Insights

Fractional marketing leadership gets described in a lot of vague ways: "an outsourced CMO," "flexible executive support," "marketing on demand." None of those describe what the work actually is day to day, and the vagueness is part of why the model gets underestimated by the people who'd benefit most from it.

Here's what it actually looks like. A fractional marketing leader owns the marketing function the same way a full-time CMO would: setting direction, deciding what gets prioritized, coordinating whoever is doing the work, whether that's an internal team, an agency, freelancers, or some mix of all three. The difference isn't the scope of responsibility. It's the time allocation and the cost structure: the organization gets senior judgment on the decisions that matter, without paying for a full-time seat, and without the multi-month search and onboarding process that a permanent executive hire requires.

The organizations that benefit most tend to share a specific problem: they have marketing activity (a website, some paid campaigns, a content calendar, maybe an agency of record) but no one senior enough to decide whether that activity adds up to a coherent strategy. Tactics multiply. Spend goes up. Nobody can say with confidence what's actually working, because no one owns the whole picture. That's a leadership gap, not a tactics gap, and it's the gap fractional leadership is built to close.

What it isn't: a part-time freelancer picking up overflow tasks, or a consultant who delivers a strategy deck and leaves execution to someone else. The value of the model depends on continuity: the same person who set the strategy is still there when it runs into a real obstacle three months later, still accountable for whether it's working, still adjusting it based on what the market and the data actually show.

For a leadership team deciding whether this model fits: the honest question isn't "can we afford a fractional CMO." It's "do we currently have anyone accountable for whether our marketing spend is working as a system, not just as a set of individual campaigns." If the answer is no, that's the gap worth closing before adding more tactics on top of an unclear foundation.

Healthcare and HealthTech marketing gets treated as a special case, and in some ways it is: longer sales cycles, more stakeholders in a single buying decision, regulatory and compliance constraints that don't exist in most other categories, and a buyer who is often more skeptical of marketing claims than buyers in any other industry. But the instinct to treat it as an entirely different discipline, requiring an entirely different playbook, tends to lead teams away from the fundamentals that still apply.

What changes: the proof required to move a buyer is different. In most categories, a compelling case study and a confident sales conversation can carry a deal a long way. In healthcare and HealthTech, buyers (whether they're a hospital system, a payer, a clinical team, or an individual provider) are evaluating risk as much as value, and they expect evidence: clinical validation where relevant, security and compliance posture, references from organizations that resemble their own, and a clear answer to what happens when something goes wrong. Messaging that works in most B2B categories, built around speed and efficiency alone, tends to fall flat here without that evidence layered underneath it.

What doesn't change: the underlying discipline of positioning. A healthcare or HealthTech company still needs a specific, defensible answer to who it's for, what problem it solves, and why it's a better choice than the alternative, including the alternative of doing nothing. The instinct to broaden the message to appeal to every possible buyer segment is just as damaging in healthcare as anywhere else, and arguably more so, because the sales cycle is long enough that an unfocused go-to-market strategy wastes months, not weeks, before the mismatch becomes obvious.

The organizations that scale successfully in this space tend to do one thing consistently: they treat the regulatory and clinical complexity as an input to the marketing strategy, not an excuse to skip strategy altogether. The complexity changes what evidence looks like and how long the cycle runs. It doesn't change the need for a clear, prioritized go-to-market plan built around a specific buyer and a specific reason to choose you.